When Was the Endocannabinoid System Discovered?

The endocannabinoid system was not discovered in a single moment but pieced together over roughly three decades, with the critical breakthroughs falling between the late 1980s and the mid-1990s. The story begins with the isolation of THC in 1964, but the system itself only came into view when researchers found the receptors that THC binds to (around 1988–1993) and then the body’s own molecules that activate those receptors (1992–1995). What emerged was something no one had predicted: a widespread signaling network that the human body uses to regulate pain, appetite, mood, immunity, and more.

THC Came First, by Accident of History

The discovery timeline is counterintuitive. Scientists identified the plant chemical before they found the biological system it hijacks. In 1964, Raphael Mechoulam and Yechiel Gaoni, working in Israel, determined the chemical structure of delta-9-tetrahydrocannabinol, better known as THC, the main psychoactive compound in cannabis.¹ That breakthrough explained what makes marijuana psychoactive, but it opened a bigger question: how does a plant molecule produce such dramatic effects on the human brain?

For the next two decades, the prevailing theory was surprisingly crude. Researchers believed THC worked by dissolving into cell membranes and disrupting their physical structure, a bit like how alcohol was once thought to act. A 1985 study, for instance, reported that psychoactive cannabinoids increased fluidity in the fatty core of brain cell membranes, lending support to this “membrane perturbant” idea.² Under that model, there was no need to look for a dedicated receptor or signaling system. THC was just gumming up cell membranes. The field almost stopped looking.

Finding the Lock Before the Key

The membrane theory began to crumble in 1988, when Allyn Howlett’s lab at St. Louis University demonstrated that brain tissue contained a specific binding site for cannabinoids, a receptor. This receptor was cloned in 1990 by Lisa Matsuda and colleagues, and it became known as CB1. It turned out to be one of the most abundant receptors in the entire brain, concentrated heavily in areas governing movement, memory, emotion, and pain. A second receptor, CB2, was cloned shortly after, in 1993. CB2 was initially considered a “peripheral” cannabinoid receptor because it showed up abundantly in immune tissue and was thought to be absent from the brain.³ Both CB1 and CB2 belong to the large family of G protein-coupled receptors, which are involved in a huge range of biological signaling.⁴

The existence of dedicated receptors changed the entire framework. The body does not build elaborate receptor systems to respond to a plant. If there is a lock, evolution put it there because the body makes its own key. That reasoning launched the next phase of discovery: the hunt for the body’s own cannabinoids.

The Body’s Own Cannabis Molecules

Mechoulam’s group struck again in 1992. Working with brain tissue from pigs, they isolated a small fatty molecule that bound to the cannabinoid receptor and mimicked many of THC’s effects. They named it anandamide, from the Sanskrit word for bliss. Anandamide behaved like a competitive partner for the receptor binding site, and it produced effects similar to psychoactive cannabinoids in laboratory tests.⁵ This was the first endocannabinoid, an internally produced molecule that uses the same receptor system that cannabis compounds target.

Three years later, in 1995, a second endocannabinoid was identified: 2-arachidonoylglycerol, or 2-AG. Two independent teams found it almost simultaneously, one in rat brain tissue and one in canine gut tissue.⁶ Unlike anandamide, 2-AG binds to both the CB1 and CB2 receptors and is present in the brain at much higher concentrations.⁷ Together, anandamide and 2-AG are considered the two principal endocannabinoids, though additional endocannabinoid-like molecules have since been identified.⁸

With receptors and their natural activators both in hand, the endocannabinoid system had a name and a basic blueprint by the mid-1990s. But understanding how the system actually operates took another round of discoveries.

How the System Works, in Reverse

Most neurotransmitter systems in the brain work in one direction: a sending neuron releases a chemical signal that crosses a tiny gap and activates a receiving neuron. Endocannabinoids do the opposite. When a receiving neuron becomes very active, it produces endocannabinoids on the spot. These fatty molecules then travel backward across the gap to the sending neuron, where they bind to CB1 receptors and tell that neuron to dial back its activity. This retrograde signaling is the signature trick of the endocannabinoid system.⁹

The effect is essentially a volume knob. When neural circuits get too loud, endocannabinoids travel upstream and turn down the signal, dampening the release of other neurotransmitters for seconds to minutes at a time. This mechanism underlies both short-term and long-term adjustments in brain circuitry.¹⁰ It explains why cannabis can blunt pain perception, reduce anxiety in some contexts, impair short-term memory, and slow reaction time: THC floods the same retrograde pathway, turning the volume knob down across many circuits at once, rather than in the precise, localized way the body’s own molecules would.

Another unusual feature is that endocannabinoids are not stored in advance. Unlike classical neurotransmitters, which sit in little vesicles waiting to be released, anandamide and 2-AG are manufactured from membrane fats on demand and broken down almost immediately after they act. The enzymes that handle cleanup are fatty acid amide hydrolase (FAAH), which primarily breaks down anandamide, and monoacylglycerol lipase (MAGL), which primarily breaks down 2-AG.¹¹ These enzymes keep endocannabinoid signaling tightly local and brief, which is why the system works as a fine-tuning mechanism rather than a blunt broadcast signal.

What the System Actually Regulates

Because CB1 receptors are scattered so widely throughout the brain and CB2 receptors are abundant in immune tissue, the endocannabinoid system touches a surprising range of bodily functions. It plays a role in metabolism, immune response, pain modulation, and neuroprotection, among others.¹² The common thread is homeostasis: when something in the body swings too far in one direction, endocannabinoid signaling helps push it back toward a set point.

This scope was not obvious at first. Early research focused almost entirely on the brain, because that is where cannabis exerts its most noticeable effects. The realization that CB2 receptors in immune cells allow endocannabinoids to regulate inflammation broadened the picture dramatically. Later work showed endocannabinoid involvement in bone density, skin health, reproductive function, and gut motility. The system turned out to be less like a single brain circuit and more like a background maintenance program running in almost every organ.

An Evolutionary Antique

One of the more striking findings in the field is how old this system is. CB1 and CB2 receptors appear to have originated in a common ancestor of all living vertebrates. A cannabinoid-type receptor has even been found in the sea squirt, a simple marine animal that diverged from the vertebrate line hundreds of millions of years ago, where it localizes to nerve fibers in a pattern suggesting an ancient role in regulating neural signaling.¹³

The system has been detected in mammals, birds, amphibians, fish, sea urchins, leeches, and mussels, and even in Hydra, one of the most primitive animals with a nervous system. Insects, however, are the notable exception. A study testing five insect species found no specific cannabinoid receptor binding and no functional response to THC. A search of the fruit fly genome turned up no recognizable versions of cannabinoid receptor genes or the FAAH enzyme.¹⁴ This appears to be a genuine loss that occurred somewhere in the insect lineage, rather than a case of the receptors never having existed. It means you cannot get a mosquito high, and it raises interesting questions about what alternative signaling systems insects developed to fill the gap.

The Endocannabinoidome and the Expanding Map

Researchers increasingly view the classic “endocannabinoid system” as the core of a larger network called the endocannabinoidome. This expanded view includes dozens of lipid-based signaling molecules that are chemically related to anandamide and 2-AG and that interact with a wider set of receptors beyond CB1 and CB2.¹⁵ Some of these molecules activate receptors involved in pain sensing, inflammation, and metabolic regulation that were not traditionally grouped with the cannabinoid system at all.

Even the basic mechanics of endocannabinoid movement remain partly unsettled. Because anandamide and 2-AG are fatty molecules, they do not dissolve easily in the watery environment inside and outside cells. How exactly they cross cell membranes has been debated for years. Studies have produced evidence both for and against a dedicated membrane transporter protein.¹⁶ Some researchers argue the transport looks like facilitated diffusion but without a clearly identified carrier, while others believe intracellular binding proteins shuttle endocannabinoids to their targets once inside the cell.¹⁷ The fact that this basic question remains open, three decades after anandamide was identified, gives a sense of how much work remains.

Why Drug Development Has Been Bumpy

Understanding the endocannabinoid system raised obvious hopes for new medicines. If you could boost or block cannabinoid signaling at will, you could potentially treat chronic pain, obesity, anxiety, epilepsy, and a range of inflammatory conditions. The first major pharmaceutical attempt, however, was a cautionary tale.

Rimonabant, a drug that blocks CB1 receptors, was approved in Europe in 2006 as an anti-obesity treatment. It worked: blocking CB1 reduced appetite and led to weight loss. But the same receptor system that regulates appetite also helps regulate mood. Patients on rimonabant developed depression and suicidal thoughts at alarming rates, and the drug was pulled from the market.¹⁸ The rimonabant episode underscored just how broadly the endocannabinoid system operates. You cannot easily block one of its functions without disrupting others.

More recent drug development has taken a different approach. Rather than blocking receptors directly, some researchers are targeting the enzymes that break down endocannabinoids, FAAH and MAGL, with the goal of gently boosting the body’s own cannabinoid signaling rather than overwhelming it with an external drug.¹⁹ The idea is that if you slow the breakdown of anandamide or 2-AG, you raise their levels only where and when they are naturally being produced, preserving the system’s built-in precision. This strategy is still largely in experimental phases, but it represents the field’s effort to learn from rimonabant’s failure.

The one clear pharmaceutical success has been cannabidiol (CBD) for epilepsy. In 2018, the FDA approved Epidiolex, a purified CBD formulation, for two severe childhood epilepsy syndromes, Dravet syndrome and Lennox-Gastaut syndrome.²⁰ CBD’s mechanism is complex and only partly involves the classical endocannabinoid system, but the approval marked a turning point for the medical legitimacy of cannabinoid-based therapies.²¹

The Runner’s High and Everyday Endocannabinoid Signaling

For decades, the euphoria some people feel after sustained aerobic exercise was attributed to endorphins, the brain’s own opioid-like peptides. That explanation had a problem: endorphin molecules are too large to cross from the bloodstream into the brain easily. More recent research has shifted attention toward endocannabinoids as a key contributor to the runner’s high. Anandamide levels in the blood rise after prolonged exercise, and anandamide crosses into the brain far more readily than endorphins do. Current thinking frames the runner’s high not as purely an endorphin or purely an endocannabinoid phenomenon but as a product of multiple neurochemical systems working together, with endocannabinoids playing a central and perhaps dominant role.²²

This connection matters beyond athletics. It suggests that regular physical activity may be one of the most reliable ways to support healthy endocannabinoid tone, and it reframes exercise-related mood benefits as partly cannabinoid-mediated. In a sense, every jogger who feels a wave of calm contentment after a long run is experiencing the endocannabinoid system doing exactly what it was selected to do across hundreds of millions of years of evolution: restoring balance after a period of stress.

What Remains Genuinely Unknown

Given that the first endocannabinoid was identified only in 1992, the field is younger than many people assume. Several foundational questions are still open. Researchers have not conclusively determined whether a dedicated transporter protein carries endocannabinoids across cell membranes or whether they simply slip through on their own. The precise roles of many endocannabinoidome molecules remain uncharacterized. And the CB2 receptor has proven harder to pin down than CB1: once thought to exist only in immune tissue, it has since been found in the brain, but its functions there are still poorly understood, earning it the label of “a cannabinoid receptor with an identity crisis” in the pharmacology literature.³

The field also faces the complication that public interest, commercial pressure, and political debate around cannabis frequently outpace the science. Many health claims made about CBD products, for example, rest on the assumption that boosting cannabinoid signaling is broadly beneficial, but the rimonabant story showed that the direction of effect matters enormously, and raising endocannabinoid tone in the wrong context could have unintended consequences. The endocannabinoid system is real, deeply important, and still only partly mapped. Three decades of research have established that it exists and sketched its outlines; the next three decades will determine how well we can put that knowledge to clinical use.